Primary Sclerosing Cholangitis Market 2021 Predicted To Reach US$ 140.4 Million By Industry Size Till 2023
SEATTLE, April 08, 2021, (PHARMIWEB) — Global Primary Sclerosing Cholangitis Market
Primary sclerosing cholangitis (PSC) is a condition that leads to long-term inflammation and scarring (fibrosis) of bile ducts in the liver. These ducts are tubes that allow the liquid (bile) produced by the liver to pass through the intestine allowing fat digestion. This disease predominantly affects men, between the 25 and 40 years of age. The damage to the ducts causes accumulation of bile acids, essential components of bile to build up in the liver leading to liver tissue damage, portal hypertension (high blood pressure in the vessels connecting the liver and the gut), and liver failure, and may increase the risk of liver cancer.
Global Primary Sclerosing Cholangitis Market – Optimistic Scenario
At present, around five products are undergoing clinical trials Phase 2 and some of them have shown good results in Phase 2. For instance, ASEOP trial, testing Obeticholic acid (OCA) for primary sclerosing cholangitis, is being conducted by Intercept Pharmaceuticals, Inc. Also, Shire Plc. completed Phase 2 clinical trial for the drug candidate LUM001 in February, 2016. If these potential molecules pass through the advanced clinical trials phase (i.e. Phase 3) and secure regulatory approval, these would be among the first-to-get-approval for this disease.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1960
Moreover, most patients in the developed economies, such as Europe and North America, where the diagnosis percentage and affordability are generally higher as compared to those in the emerging economies, which would result in higher adoption rate of novel products with significantly high yearly cost (i.e. more than US$ 50,000 for orphan drugs). Due to the above mentioned factors, the global primary sclerosing cholangitis market is expected to reach US$ 140.4 million by 2023.
However, withdrawal of potential therapeutic molecules from late-stage clinical trials have limited the availability of efficient treatment, thus compelling the patient pool to adopt alternative treatment therapies such as bile acid sequestrants, antibiotics, antihistamines, opioid antagonists, and ursodeoxycholic acid (UDCA).
According to a study published in the Gastroenterology and Hepatology Journal, in 2016, current medical therapies such as ursodeoxycholic acid improves liver enzymes. However, it does not prevent the progression of PSC or reduce the risk of recurrence. Thus, unavailability of approved drugs targeting the condition in practical medical use is a factor hindering growth of the global PSC market.
Increasing incidence of liver failure and bile cancer associated with PSC to boost market growth
Surging prevalence of diseases associated with PSC, such as liver cancer and inflammatory bowel disease, is a vital factor expected to enhance the therapeutic adoption of efficient drugs to manage the condition, thus driving growth of the primary sclerosing cholangitis market. According to the World Journal of Gastroenterology, 2017, inflammatory bowel disease (IBD) is diagnosed in around 50-80% of the patients with PSC, with ulcerative colitis (UC) comprising around 80-90% of these cases.
Furthermore, individuals with PSC are at a greater risk of developing cancer in bile ducts, called cholangiocarcinoma, as compared to the general populace. According to the National Organization for Rare Disorders (NORD), in 2016, around 8% to 15% of the PSC-affected individuals eventually develop cholangiocarcinoma and have enhanced risk of developing gall bladder cancer. Moreover, NORD states that patients with PSC are at a greater risk of developing Crohn’s disease, colon cancer, and immune-mediated disorders such as thyroid disease, Peyronie’s disease, retroperitoneal fibrosis, psoriasis, rheumatoid arthritis, Celiac disease, and others.
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/1960
Currently, liver transplant is the only known cure for primary sclerosing cholangitis and is one of the major causes for liver transplantation in the U.S. However, as per the survey by Mayo Clinic, the disease is expected to recur in the transplanted liver in 27.2% of the patients, thereby demanding efficient and affordable therapeutic solutions to cater to unmet patient needs. According to the United Network for Organ Sharing (UNOS), 2011, estimated bill charges of a liver transplant procedure is around US$ 577,100 in the U.S.
Thus, the necessity to provide affordable treatment, owing to high costs associated with liver transplantation coupled with increasing risk factors resulting in the development of serious disorders are major factors that are expected to increase the adoption of PSC drugs, in turn favoring market growth in the near future.
However, the major players operating in the global primary sclerosing cholangitis market include Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Allergan Plc., Shire Plc., Durect Corporation, Conatus Pharmaceuticals, Inc., Sirnaomics, Inc., and Shenzhen HighTide Biopharmaceutical Ltd.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/primary-sclerosing-cholangitis-market-to-reach-us-1404-million-by-2023-1021
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Overview
- Optimistic, Likely and Pessimistic Overview
- Report Description
- Market Dynamics, Pipeline, and PEST Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- PEST Analysis
- Pipeline Analysis
- Initiatives Focusing On PSC Support And Research
- Reason For Phase 3 Drug Withdrawal
- Challenges Faced by Orphan Drug Candidates
- Epidemiology
- Market Dynamics
- Global Primary Sclerosing Cholangitis Market, By Drug
- Introduction
- BTT1023
- Research Details
- GS-9674
- Research Details
- NGM282
- Research Details
- OCA
- Research Details
- Cenicriviroc
- Research Details
- LUM001
- Research Details
- DUR928
- Research Details
- norUDCA
- Research Details
- HTD1801
- Research Details
- IDN-7314
- Research Details
- STP705
- Research Details
- Global Primary Sclerosing Cholangitis Market, By Region
- Introduction
- North America
- Regional Overview
- Latin America
- Regional Overview
- Europe
- Regional Overview
- Asia Pacific
- Regional Overview
- Middle East
- Regional Overview
- Africa
- Regional Overview
- Competitive Landscape
- Company Profiles
- Analyst Views
- Section
- References
- Research Methodology
- About us and Sales Contact
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- CDN Newswire
